Refining the Who, When, and How of SGLT2-Inhibitors of Patients with HFpEF Part 2

As SGLT2-inhibitors become more relevant in multiple disease states with recent data surrounding HFpEF, we will discuss the real world implementation of the medication. We will also review how cost and formularies may affect our decision.  The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.